Clinical trials
Completed Leukemia, Myelomonocytic, Chronic trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| Groupe Francophone des Myelodysplasies | 3 |
| Traws Pharma, Inc. | 3 |
| Astex Pharmaceuticals, Inc. | 2 |
| Novartis Pharmaceuticals | 2 |
| Pfizer | 2 |
| Institut Paoli-Calmettes | 1 |
| Janssen Research & Development, LLC | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Millennium Pharmaceuticals, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelomonocytic, Chronic | 24 |
| Myelodysplastic Syndromes | 18 |
| Leukemia, Myeloid, Acute | 15 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
| Lymphoma, B-Cell, Marginal Zone | 5 |
| Lymphoma, Large B-Cell, Diffuse | 5 |
| Lymphoma, Mantle-Cell | 5 |
| Myeloproliferative Disorders | 5 |
| Blast Crisis | 4 |
| Burkitt Lymphoma | 4 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.